Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 7:23 AM ET

Pharmaceuticals

Company Overview of Zensun (Shanghai) Sci. &Tech. Co., Ltd.

Company Overview

Zensun (Shanghai) Sci. &Tech. Co., Ltd., a bio-tech pharmaceutical company, engages in the research and development of anti-tumor and anti-heart failure drugs. Its products include NEUCARDIN, a recombinant human neuregulin peptide for the treatment of heart failure; recombinant human ErbB3 fragment, a therapeutic tumor vaccine; recombinant human neuregulin-1, an anti-heart failure drug; and recombinant human ErbB3 fragment immunization, a therapeutic cancer vaccine. The company’s products in pipeline include vaccines to overcome the immuno suppression; neuregulin mutants; enzyme inhibitors; and therapeutic antibodies for small cell lung cancer. It also offers services in the areas of animal ...

No. 68 Ju LI Road

Zhangjiang

Hi-tech Park

Shanghai,  201203

China

Phone:

86 21 5080 2627

Fax:

86 21 5080 2621

Key Executives for Zensun (Shanghai) Sci. &Tech. Co., Ltd.

Founder, Chief Executive Officer and Chief Scientist
Vice President of Finance
Executive Vice President of Global Clinical Trial and President of Zensun USA Inc
Executive Vice President of Domestic Drug Development, Medical & Regulatory Affairs
Vice President of Administration & Human Resources and Secretary of Board
Compensation as of Fiscal Year 2014.

Zensun (Shanghai) Sci. &Tech. Co., Ltd. Key Developments

SciClone Pharmaceuticals, Inc. and Zensun (Shanghai) Science & Technology Co., Ltd. Enters into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin for the China Market

SciClone Pharmaceuticals, Inc. announced that it has entered into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin(TM), a novel, first-in-class therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure. Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 that has been clinically shown to directly improve cardiac function, reverse ventricular remodeling and increase the survival of heart failure patients. Six Phase 2 studies with Neucardin have been conducted in China, Australia and the United States, including three Phase 2b studies in China. The China Phase 2b survival study demonstrated that Neucardin was well tolerated and showed a significant decrease in mortality and improved survival in patients with CHF. A New Drug Application (NDA) was submitted to and accepted by the China Food and Drug Administration (CFDA) in 2012.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zensun (Shanghai) Sci. &Tech. Co., Ltd., please visit www.zensun.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.